文献速递糖尿病

非空腹50克1小时口服葡萄糖激发试验筛查囊性纤维化相关糖尿病

Screening for Diabetes and Prediabetes in Cystic Fibrosis Using a Nonfasting 50-Gram 1-Hour Oral Glucose Challenge Test.
PubMed 文献 · Diabetes Care · 2026-01-01

囊性纤维化(CF)成人中囊性纤维化相关糖尿病(CFRD)患病率近半,但推荐的口服葡萄糖耐量试验(OGTT)筛查率低。本研究评估非空腹50克1小时口服葡萄糖激发试验(GCT)作为CFRD和糖尿病前期(pre-CFRD)一线筛查的价值,并确定高灵敏度切点。185例≥10岁无已知糖尿病的CF患者中,GCT血浆葡萄糖(GCTpl)识别pre-CFRD或CFRD的ROC-AUC为0.73,优于随机血糖和HbA1c;GCTpl 147 mg/dL对CFRD灵敏度90%、特异度58%,可减少56%的OGTT需求。

要点

  • 非空腹50g 1h GCT可作为CFRD一线筛查,GCTpl切点147 mg/dL灵敏度90%。
  • GCTpl识别pre-CFRD或CFRD的ROC-AUC为0.73,优于随机血糖和HbA1c。
  • 采用该切点可减少56%的OGTT需求,避免低风险个体行OGTT。

核心结论

  • 非空腹50g 1h GCT是实用的CFRD筛查方法,切点147 mg/dL对CFRD灵敏度90%、特异度58%,可减少56%的OGTT需求。

研究设计与样本

  • 研究纳入185例≥10岁、无已知糖尿病的CF患者,先测随机血浆和毛细血管血糖,再行临床GCT测1h血浆葡萄糖,另日测HbA1c和OGTT。
  • 采用ROC曲线分析GCTpl识别CFRD和pre-CFRD的效能。

主要发现

  • 185例中94例糖耐量正常、81例pre-CFRD、10例CFRD。
  • GCTpl识别pre-CFRD或CFRD的ROC-AUC为0.73(95% CI 0.65-0.80),高于随机血浆葡萄糖的0.56(0.48-0.65,P=0.003)、随机毛细血管葡萄糖的0.55(0.46-0.63,P=0.002)和HbA1c的0.62(0.53-0.67,P=0.02)。
  • GCTpl识别CFRD的ROC-AUC为0.75(0.64-0.86),随机血浆葡萄糖为0.64(0.42-0.87),HbA1c为0.56(0.39-0.73)。
  • GCTpl 147 mg/dL对CFRD的灵敏度为90%、特异度为58%,可减少56%的OGTT需求。

关键数值与推荐

  • GCTpl切点147 mg/dL用于筛查CFRD,灵敏度90%、特异度58%。
  • GCTpl识别pre-CFRD或CFRD的ROC-AUC为0.73(95% CI 0.65-0.80)。

临床怎么用

  • 对≥10岁无已知糖尿病的CF患者,可考虑非空腹50g 1h GCT作为一线筛查。
  • GCTpl≥147 mg/dL者建议进一步行OGTT以确诊CFRD。
  • GCTpl<147 mg/dL的低风险个体可暂免OGTT,减少筛查负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cystic fibrosis (CF)-related diabetes (CFRD) affects nearly half of adults with CF, but screening rates with the recommended oral glucose tolerance test (OGTT) are low. We evaluated the utility of a nonfasting, 50-g, 1-h oral glucose challenge test (GCT) as first-line screening for CFRD and pre-CFRD. The objectives were to define a cutoff that provides high sensitivity and reasonable specificity, and to determine how GCT compares with other opportunistic tests. RESEARCH DESIGN AND METHODS: Participants with CF ≥10 years old, without known diabetes, had baseline random plasma and capillary glucose (RPG and RCG), then underwent an in-clinic GCT for collection of 1-h plasma glucose (GCTpl). This was followed by hemoglobin A1C (HbA1c) and OGTT on a separate day. Receiver operating characteristic (ROC) curves were generated for identifying CFRD and pre-CFRD. RESULTS: Of 185 participants, 94 had normal glucose tolerance, 81 had pre-CFRD, and 10 had CFRD. For detecting pre-CFRD or CFRD, GCTpl had an area under the ROC curve (ROC-AUC) of 0.73 (95% CI 0.65-0.80), higher than ROC-AUCs for RPG of 0.56 (0.48-0.65, P = 0.003), RCG of 0.55 (0.46 = 0.63, P = 0.002), and HbA1c of 0.62 (0.53-0.67, P = 0.02). The ROC-AUC for detecting CFRD was 0.75 (0.64-0.86) for GCTpl, 0.64 (0.42-0.87) for RPG, and 0.56 (0.39-0.73) for HbA1c. A GCTpl of 147 mg/dL provides 90% sensitivity and 58% specificity for detecting CFRD and could reduce the OGTTs needed by 56%. CONCLUSIONS: GCT offers a practical, in-clinic method for CFRD screening. This spares low-risk individuals from OGTT, while maintaining high sensitivity for CFRD.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Maher MD, Vigers T, Kohler C, et al. Screening for Diabetes and Prediabetes in Cystic Fibrosis Using a Nonfasting 50-Gram 1-Hour Oral Glucose Challenge Test. Diabetes Care. 2026. PMID: 41911242. doi:10.2337/dc25-2806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。